摘要:
The present invention relates compounds of the formula (I): wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of: (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l) and R , R , R ,R , R , R , R , R , R , R , R , R , R , R and R are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.
摘要:
A compound of formula (I) (wherein R is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R and R may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N -R •Y (R is a hydrocarbon group; Y is a counter anion); R is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G is a bond, CO or SO2; G is CO, SO2, NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).
摘要翻译:式(I)的化合物(其中R 1为氢原子,可被取代的烃基,可被取代的非芳族杂环基,R 2为可被取代的烃基, 可以被取代的非芳族杂环基或R 1和R 2可以与A一起彼此结合形成可被取代的杂环基; A是N或N + (R 5为烃基; Y 1为抗衡阴离子); R 3为可被取代的环状烃基或可被取代的杂环基; n为 为0或1; R 4为氢原子,可被取代的烃基,可被取代的杂环基,可被取代的烷氧基,可被取代的芳氧基或氨基 E可以被除氧基以外的基团取代的二价脂族烃基; G 1是CO或SO 2键; G 2是CO,SO 2,NHCO,CONH o r OCO; J为次甲基或氮原子; Q和R分别为可以被取代的键或二价C 1-3脂族烃; 条件是当G 2为OCO时J为次甲基,当另一个为键时Q和R之一不为键,并且当G 1为键时,Q和R各自不被氧代基取代 )或其盐具有有效的CCR5拮抗活性,并且可以有利地用于治疗或预防人类各种HIV(例如AIDS)的感染性疾病。
摘要:
NF- kappa B inhibitors containing as the active ingredient benzoquinone derivatives represented by general formula (I), hydroquinone compounds thereof or salts of the same, wherein R1, R2 and R3 independently represent each H, C1-5 alkyl or C1-5 alkoxy; R4 represents H, hydroxy-methyl, alkyl or optionally esterified or amidated carboxy; Z is represented by formula (A); and n is from 0 to 6.
摘要:
This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula (I), where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula (I) are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and the compounds of formula (I). This invention is further directed to methods comprising administering to a human or other animal a combination of a functional somatostatin antagonist such as an alpha-2 adrenergic agonist and a compound of formula (I).
摘要:
The present invention is directed to compounds having anti quorum sensing activity, anti-inflammatory activity or both, compositions comprising same, and methods of using same, such for treating a subject afflicted with a disease.
摘要:
A preparation method according to the present invention makes it possible to industrially produce large amounts of highly pure optically active tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate in high yield by use of commercially available reagents and solvents. In addition, the use of novel intermediates according to the present invention makes it possible to produce highly pure optically active tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate in high yield.
摘要:
The present disclosure relates, in general, to compounds useful as inhibitors of fucosidase enzymes, and to methods and compositions for the treatment of tumors or cancers, such as liver disorders and liver tumors (e.g., hepatocellular carcinoma), with a compound as disclosed herein.
摘要:
본 발명은 신규 테트라하이드로피리디놀 유도체 화합물, 이를 유효성분으로 포함하는 암 예방 또는 치료용 약제학적 조성물, 건강기능식품에 관한 것이다. 본 발명의 신규 테트라하이드로피리디놀(tetrahydropyridinol) 유도체 화합물은 베타-카테닌(β-catenin) 발현의 하향 조절, GSK-3β(glyco-gensynthase kinsase 3-β) 발현의 상향 조절 또는 이케드헤린(E-cadherin) 발현의 상향 조절을 통한 wnt/β-catenin 신호 방해 기작으로 암세포의 증식 및 침투를 억제할 수 있을 뿐만 아니라, CDK2의 발현 억제 및 p21과 p27의 발현 증대를 통한 암세포의 세포주기중지(cell cycle arrest)를 유도할 수 있으므로 암을 예방 또는 치료할 수 있는 물질로서 약리학적 조성물과 같은 의약품은 물론이고, 건강기능식품 등으로 활용할 수 있고, 본 발명의 신규 테트라하이드로피리디놀 유도체는 비-종양성 세포에는 세포독성을 보이지 않기 때문에 장기적 사용에도 안전한 이점을 가진다.